Equities Analysts Set Expectations for INKT FY2030 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Research analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of MiNK Therapeutics in a report issued on Wednesday, April 1st. HC Wainwright analyst E. Bodnar forecasts that the company will earn $1.31 per share for the year. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Tuesday, March 31st. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.14.

Separately, Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Stock Performance

MiNK Therapeutics stock opened at $10.69 on Thursday. The stock has a market cap of $53.13 million, a PE ratio of -3.60 and a beta of 0.35. The stock has a 50-day moving average of $10.88 and a two-hundred day moving average of $12.22. MiNK Therapeutics has a one year low of $6.34 and a one year high of $76.00.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC boosted its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.87% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.